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Anidulafungin for Candida glabrata Infective Endocarditis
We briefly report on a patient with infective endocarditis (IE)due to Candida glabrata that was treated with a double dos-
age of anidulafungin. A 65-year-old woman was admitted on 28
May 2011 with fever and weight loss. Important comorbidities
were hepatitis C virus (HCV)-related cirrhosis, pancytopenia due
to spleen enlargement and previous episodes of autoimmune he-
molytic anemia and thrombocytopenia, multiple cardiosurgeries
during a 20-year period (in 1980, aortic andmitral valve substitu-
tion, in 2001, prosthetic mitral valve implanted for IE, and in
2005, bioprosthetic tricuspid valve implant and intravascular elec-
trocatheters). In October 2010, the patient had a femoral fracture
which needed a prosthetic implant; in December 2010,C. glabrata
candidemiawas treatedwith intravenous and oral voriconazole by
the attending physician for 21 days in another hospital. No vori-
conazole plasma concentration study was performed at that time.
During the current admission, on 28 May 2011, transesopha-
geal echocardiography (TEE) showed a vegetation 8mm in length
on the anterior medial corner and a vegetation of 9 by 13 mm on
the posterolateral corner of the bioprosthetic tricuspid valve; em-
pirical intravenous (i.v.) treatmentwas started by the cardiologists
with 60 mg of gentamicin two times a day, 300 mg of rifampin
three times a day, and 350 mg of vancomycin two times a day. All
drawn blood cultures were positive for C. glabrata, and liposomal
amphotericin B was administered and then switched for infusion
intolerance to 100 mg of anidulafungin i.v. daily for 5 days and
then 200 mg daily, according to the 2009 IDSA guidelines (5).
Laboratory parameters were as follows: procalcitonin, 22.3 ng/ml;
C-reactive protein, 38 mg/dl; fibrinogen, 297 mg/dl; hemoglobin,
9.7 g/dl; white blood cells, 2.27  109/liter; platelets, 51  109/
liter; aspartate transaminase, 76 UI/liter; alanine transaminase, 46
UI/liter; gamma-glutamyl transferase, 246 UI/liter; and albumin,
2.7 g/dl.
In vitro C. glabrata sensitivities were determined with Sensitre
YeastOne (Trek Diagnostic, Inc.) with the following results: am-
photericin, 0.5 mg/liter; fluconazole, 8 mg/liter; caspofungin,
0.125 mg/liter; anidulafungin, 0.125 mg/liter; voriconazole, 0.125
mg/liter; and itraconazole, 0.5 mg/liter. Blood cultures were neg-
ative 72 h after the beginning of antifungal treatment. Anidulafun-
gin at 200 mg daily was given for 2 weeks before cardiosurgery (3
to 17 June) and for 4 weeks thereafter, including 17 days in the
intensive care unit due to a right lung hemorrhagic lesion which
needed a further surgical approach.
The plasma concentrations of anidulafungin were studied with
both dosages and are illustrated in Fig. 1. Anidulafungin plasma con-
centrationswere determined by a validated ultra-performance liquid
chromatography–tandem mass spectrometry method (UPLC–MS-
MS) (2). Chromatographic separation was performed using an Ac-
quity UPLC HSS T3, 1.8-m, 2.1- by 150-mm column (Waters,
Milford, CT). The assay response was linear over the concentra-
tion range of 0.059 to 15 mg/liter with a lower limit of quantifica-
tion of 0.059 mg/liter.
The results of the monitoring of plasma concentrations are
illustrated in Fig. 1. The maximum andminimum concentrations
of drug in serum (Cmax andCmin),Cmax/MIC ratio, and area under
the concentration-time curve at 24 h (AUC24)/MIC ratio were
7.93 mg/liter versus 10.19 mg/liter, 3.46 mg/liter versus 6.41 mg/
liter, 63.4 versus 81.5, and 1,012.0 versus 1,563.2 for the standard
dosage and double dosage of anidulafungin, respectively. AUC
values were as follows: 126.50 mg · h/liter versus 195.40 mg · h/li-
ter. No side effects were observed; in particular, there were no
infusional side effects nor further increase of the hepatic enzymes.
The patient was discharged to rehabilitation on July 19, where
treatment was continued with voriconazole. On October 2011, a
new TEE showed no signs of IE.
According to the 2009 IDSA guidelines, echinocandins are pre-
ferred as the initial therapy for candidemia and should be admin-
istered for 2weeks after the first negative blood culture (5). Anidu-
lafungin has potent in vitro activity against sessile Candida cells
within biofilms, and studies have clearly shown that the rate of
Candida glabrata biofilm production is equal to that of Candida
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FIG 1 Anidulafungin plasma concentration for standard (100 mg QD [once a day]) and double dosage (200 mg QD) intravenous administration.
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parapsilosis, typically isolated in central venous catheter-related
candidemia (6, 7). The same guideline recommended with a BIII
level of evidence a double daily dosage of an echinocandin for
treatment of Candida IE, with evidence mostly based on case re-
ports with caspofungin—data are limited on the safety and effi-
cacy of double-dosage anidulafungin (5).
It has in fact been proposed that Candida IE may follow can-
didemia after as many as 240 days (153 days in our case), thus
requiring appropriate treatment of candidemia, as well as preco-
cious diagnostic and follow-up considerations for IE (3, 4), espe-
cially when prosthetic valves are present. Conventional treatment
for IE by Candida spp. may be hampered by renal toxicity or
failure or leukopenia, making a combination therapy with lipid
formulation of amphotericin B and flucytosine difficult. Several
studies showed how medical management of candidemia in pa-
tients with prosthetic valves probably needs prolonged courses of
intravenous antifungals owing to the possibility of developing IE.
Specific literature breakpoints for anidulafungin for C. glabrata
bloodstream infections and IE have not been clearly defined. Ac-
cording to EUCAST, the following parameters are probably pre-
dictive of efficacy: Cmax, 7 mg/liter; Cmin, 3 mg/liter; and AUC24,
110mg · h/liter. Values forCmax/MIC andAUC24/MIC ratios have
not been established. In our case, pharmacokinetic parameters
were achieved with both dosages of anidulafungin, which, accord-
ing to Andes et al., seems to have a more linear kinetic profile of
fungicidal activity against Candida spp., suggesting that the fun-
gicidal activity may improve with increasing dosages (1). The ef-
fectiveness of 200mgof anidulafungin daily is shown in our report
by the early achievement of negative blood cultures without any
side effect, even if the patient had serious comorbidities which
may have altered pharmacokinetic parameters. However, we
should remember that the definitive cure of such patients requires
surgical and medical treatment.
In conclusion, we report the pharmacokinetic parameters of
200 mg of anidulafungin in a case of C. glabrata IE, successfully
treated with surgery and a 6-week intravenous antifungal treat-
ment followed by prolonged voriconazole administration.No side
effects were recorded during the 6-week course, and there was no
relapse by 11 months after the cardiosurgery.
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